AstraZeneca plc (AZN) Expected to Post Earnings of $0.42 Per Share
Wall Street analysts predict that AstraZeneca plc (NYSE:AZN) will announce $0.42 earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have provided estimates for AstraZeneca’s earnings, with estimates ranging from $0.34 to $0.53. AstraZeneca reported earnings of $1.21 per share in the same quarter last year, which would indicate a negative year over year growth rate of 65.3%. The business is expected to issue its next quarterly earnings report before the market opens on Friday, February 2nd.
On average, analysts expect that AstraZeneca will report full year earnings of $1.88 per share for the current financial year, with EPS estimates ranging from $1.82 to $2.02. For the next financial year, analysts expect that the business will report earnings of $1.78 per share, with EPS estimates ranging from $1.67 to $1.94. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow AstraZeneca.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the company posted $1.32 EPS. The company’s revenue was up 9.4% on a year-over-year basis.
AZN has been the topic of a number of analyst reports. JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Leerink Swann upped their price objective on shares of AstraZeneca from $31.00 to $34.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Finally, BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the company a “buy” rating in a research note on Wednesday, November 15th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $34.20.
A number of hedge funds and other institutional investors have recently modified their holdings of AZN. Dorsey & Whitney Trust CO LLC lifted its stake in shares of AstraZeneca by 0.7% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock valued at $454,000 after buying an additional 94 shares in the last quarter. Financial Counselors Inc. lifted its stake in shares of AstraZeneca by 2.7% in the second quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock valued at $234,000 after buying an additional 182 shares in the last quarter. FTB Advisors Inc. lifted its stake in shares of AstraZeneca by 3.2% in the second quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after buying an additional 200 shares in the last quarter. Logan Capital Management Inc. lifted its stake in shares of AstraZeneca by 1.7% in the second quarter. Logan Capital Management Inc. now owns 22,327 shares of the company’s stock valued at $761,000 after buying an additional 377 shares in the last quarter. Finally, Veritable L.P. lifted its stake in shares of AstraZeneca by 6.5% in the second quarter. Veritable L.P. now owns 6,877 shares of the company’s stock valued at $234,000 after buying an additional 419 shares in the last quarter. 14.75% of the stock is currently owned by institutional investors and hedge funds.
Shares of AstraZeneca (NYSE AZN) traded up $0.25 during midday trading on Thursday, reaching $35.65. 3,017,976 shares of the company’s stock traded hands, compared to its average volume of 2,561,584. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. AstraZeneca has a 1 year low of $26.51 and a 1 year high of $35.92. The firm has a market cap of $90,281.55, a PE ratio of 12.78, a P/E/G ratio of 3.42 and a beta of 0.72.
TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/01/14/astrazeneca-plc-azn-expected-to-post-earnings-of-0-42-per-share.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.